Standard Operating Procedure for Lifecycle Compliance Review of Marketed Products
| Department | Regulatory Affairs |
| SOP No. | RA/2026/683 |
| Supersedes | NA |
| Page No. | 1 of X |
| Issue Date | 11/04/2026 |
| Effective Date | 11/04/2026 |
| Review Date | 11/04/2028 |
Purpose
This Standard Operating Procedure (SOP) establishes a uniform and controlled approach for conducting lifecycle compliance reviews of marketed products to ensure ongoing adherence to applicable regulatory requirements, quality standards, and post-approval commitments. The objective is to maintain product compliance, manage variations efficiently, and mitigate risks associated with regulatory changes or market conditions throughout the product lifecycle.
Scope
This SOP applies to all marketed pharmaceutical products regulated by the organization, encompassing all dosage forms, packaging, labeling, manufacturing sites, and associated regulatory documentation. It covers lifecycle compliance activities including but not limited to post-approval changes, variations, renewals, and periodic regulatory assessments. This SOP is applicable to the Regulatory Affairs department and relevant cross-functional teams involved in lifecycle management. It excludes investigational products and products that have been withdrawn from the market.
Responsibilities
- Regulatory Affairs Specialists: Execute lifecycle compliance reviews, prepare assessments, and submit variations or amendments to regulatory authorities.
- Quality Assurance (QA): Review regulatory submissions, ensure alignment with GMP and quality systems, and approve relevant documentation.
- Product Managers: Provide product-specific information, support change implementation, and facilitate cross-department coordination.
- Compliance Officer: Monitor compliance status and escalate deviations or regulatory risks.
- Document Control: Ensure proper filing, version control, and archiving of lifecycle compliance documentation.
Accountability
The Head of Regulatory Affairs holds overall accountability for the implementation, adherence, periodic review, and continuous improvement of this SOP. This role is responsible for ensuring compliance with regulatory requirements, managing escalation of issues, and validating the effectiveness of lifecycle compliance processes.
Procedure
1. Preparation and Planning: Regulatory Affairs shall maintain an updated product register including marketing approvals, authorized indications, dosage forms, sites, and packaging configurations. Using this register, plan periodic lifecycle compliance reviews based on product risk, regulatory timelines, and authority requirements.
2. Prerequisites: Ensure all current marketing authorizations, regulatory communications, and change history documentation are accessible. Confirm involvement of cross-functional stakeholders such as QA, manufacturing, and product management.
3. Compliance Review Execution: Conduct a comprehensive review of each marketed product’s regulatory status, reviewing the following elements:
- Current marketing authorization and approved specifications
- Pending or approved post-approval changes or variations
- Pharmacovigilance commitments and reported safety updates
- Regulatory authority notifications related to product lifecycle
- Inspection observations or compliance-related findings affecting the product
- Product labeling and packaging compliance with current guidelines
4. In-Process Controls & Verification: Validate that all post-approval changes have been fully implemented and authorized prior to execution. Verify that manufacturing, analytical, and stability data meet regulatory commitments and internal QA standards.
5. Acceptance Criteria: Identify any discrepancies, gaps, or deviations from regulatory requirements. Document reasons and corresponding corrective action plans. Cases where deviations impact product compliance shall be escalated immediately.
6. Handling Deviations and Escalations: If non-compliance or gaps are detected, record findings in a deviation report or CAPA system. Notify Quality Assurance and senior management for mitigation and corrective steps including potential regulatory submissions or notifications.
7. Review and Approval of Reports: Compile a Lifecycle Compliance Review Report detailing findings, recommendations, and actions. Obtain approvals from Regulatory Affairs Head and QA for closure.
8. Documentation and Record Retention: Archive all lifecycle compliance documents, review reports, change submissions, and approvals in the Document Control system as per retention policy. Maintain traceability and confidentiality.
9. Closure and Follow-up: Confirm implementation of corrective actions and closure of any deviations. Repeat lifecycle compliance review cycle as scheduled or prompted by regulatory changes.
10.Training and Awareness: Ensure all personnel involved in lifecycle compliance activities are trained on this SOP and regulatory updates.
This systematic and documented approach ensures continuous product compliance with evolving regulatory standards and supports effective risk management throughout the marketed product’s lifecycle.
Abbreviations
- CAPA: Corrective and Preventive Action
- GMP: Good Manufacturing Practices
- QA: Quality Assurance
- SOP: Standard Operating Procedure
- RA: Regulatory Affairs
- PV: Pharmacovigilance
Documents
- Product Lifecycle Compliance Review Report Template (Annexure-1)
- Post-Approval Change Tracking Log (Annexure-2)
- Regulatory Authority Communication Record (Annexure-3)
References
- ICH Q12 – Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management
- EU Guidelines on Good Manufacturing Practices – Chapter 1: Pharmaceutical Quality System
- FDA Guidance for Industry: Postapproval Changes to Drug and Biological Products
- Company Quality Manual and Document Control Procedures
- Applicable National Regulatory Authority guidelines on variations and lifecycle management
Version
1.0
Approval
| Prepared By | |
| Checked By | |
| Approved By |
Annexures
Annexure-1: Product Lifecycle Compliance Review Report Template
Purpose: To document the comprehensive review of regulatory compliance status for a marketed product through its lifecycle.
| Product Name | Example Product XYZ |
| Dosage Form | Tablet |
| Review Date | 01/04/2026 |
| Reviewed By | Regulatory Affairs Specialist |
| Regulatory Status Summary | All marketing authorizations current and valid |
| Post-Approval Changes Status | 3 approved variations implemented, 1 variation pending submission |
| Compliance Findings | No deviations or non-conformities identified |
| Corrective Actions | N/A |
| Remarks | Next review scheduled for 01/10/2026 |
| Approvals | Head of Regulatory Affairs, Quality Assurance |
Annexure-2: Post-Approval Change Tracking Log
Purpose: To maintain a record of all post-approval changes, their submission status, and approval status through the regulatory lifecycle.
| Change ID | Description | Submission Date | Regulatory Authority | Status | Implementation Date |
|---|---|---|---|---|---|
| CHG-2026-001 | Increase batch size | 15/02/2026 | FDA | Approved | 28/03/2026 |
| CHG-2026-002 | Change in manufacturing site | 01/03/2026 | EMA | Pending | N/A |
| CHG-2026-003 | Label update for storage conditions | 10/01/2026 | MHRA | Approved | 20/02/2026 |
Annexure-3: Regulatory Authority Communication Record
Purpose: To maintain documentation of communications, queries, and responses exchanged with regulatory authorities during lifecycle compliance activities.
| Date | Reference Number | Authority | Subject | Summary | Follow-up Actions |
|---|---|---|---|---|---|
| 05/03/2026 | FDA-12345 | FDA | Review of batch size increase | Request for additional stability data | Submit requested data by 30/04/2026 |
| 20/03/2026 | EMA-67890 | EMA | Clarification on manufacturing site transfer | Provided additional qualification documents | Awaiting approval decision |
Revision History
| Revision Date | Revision No. | Revision Details | Reason for Revision | Approved By |
| 11/04/2026 | 1.0 | Initial issue | New SOP creation |